Genetic Technologies

Genetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The GeneType/Corporate segment includes tha GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Earnings data Q1 2024

Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. It operates through the following segments: EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment deals with AffinityDNA branded test sales and expenses. The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987, and is headquartered in Fitzroy, Australia.

MELBOURNE, Australia, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 1,250,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company's ordinary shares, at a purchase price of $5.25 per ADS for gross proceeds of approximately $6.56 million.

Genetic Technologies Announces Closing of $6.56 Million Registered Direct Offering

Obalon Therapeutics

Addex Therapeutics

Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone. Genetic Technologies is an Australia-based molecular diagnostics company which offers predictive testing and assessment tools to help physicians proactively manage women's health.

Why Addex, Genetic Technologies And Obalon Are Moving Today

MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,250,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company's ordinary shares, at a purchase price of $5.25 per ADS. The closing of the offering is expected to occur on or about January 25, 2021, subject to the satisfaction of customary closing conditions.

Genetic Technologies Announces $6.56 Million Registered Direct Offering

Shares of GENE stock are rising on Thursday morning after Genetic Technologies provided a positive update regarding two important initatives. The post GENE Stock Alert: 10 Things to Know About Genetic Technologies As Shares Rocket Higher appeared first on InvestorPlace.

GENE Stock Alert: 10 Things to Know About Genetic Technologies As Shares Rocket Higher

The stock price of Genetic Technologies Limited (NASDAQ: GENE) is trading at over 80% pre-market today. This is why it happened.

GENE Stock Price Increases Over 80% Pre-Market: Why It Happened

MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company's offering to include Germline Testing division.

Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

MELBOURNE, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce an interview with its interim-CEO, Dr. Jerzy Muchnicki aired on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.

Genetic Technologies Interview Aired on Bloomberg International on the RedChip Money Report

MELBOURNE, Australia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, Dr. Jerzy Muchnicki, will share insight into the company's recent developments during an investor webinar on Thursday, November 19, 2020 at 4:15 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation.

Genetic Technologies to Hold Investor Webinar and Q&A Session on November 19

MELBOURNE, Australia, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on the development of the Company’s COVID-19 Risk Test.

Genetic Technologies Provides Update on COVID-19 Risk Test

MELBOURNE, Australia, Sept.  15, 2020  (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ:GENE) (“Genetic Technologies” or the "Company") is developing a Polygenic Risk Score (PRS) test for COVID-19 which may enable an assessment of risk of an individual developing a serious disease should they contract the virus. The test is intended to predict ‘disease severity’ using a combination of genetic and clinical information. The Company is pleased to provide the following update on the test development program:

Genetic Technologies Provides Update on COVID-19 Disease Severity Test Development

MELBOURNE, Australia, Sept.  11, 2020  (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”) is delighted to announce that initial sales of its GeneType for Breast Cancer Risk Assessment have now commenced in the United States via an online health platform, elicity by InTeleLabs, an independent telehealth and personalised medicine company. This portal is secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant.

Genetic Technologies Announces US Sales Have Commenced via Online Health Platform

MELBOURNE, Australia, Sept.  01, 2020  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, is pleased to announce that it received notification from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company has met the minimum stockholders equity requirement set forth in Listing Rule 5550(b)(1).

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

MELBOURNE, Australia, July  20, 2020  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 1,025,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $5.00 per ADS for gross proceeds of approximately $5.1 million.

Genetic Technologies Announces Closing of $5.1 Million Registered Direct Offering

US Global Jets ETF

SPDR S&P Regional Banking ETF

VanEck Mortgage REIT Income ETF

Invesco Dynamic Leisure and Entertainment ETF

Invesco S&P SmallCap Health Care ETF

Royal Caribbean Cruises

Vaccine hopes and some upbeat banking earnings have boosted the risk-on sentiments in Wall Street.

Vaccine Hopes Boost These Sectors & ETFs

MELBOURNE, Australia, July  16, 2020  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,025,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $5.00 per ADS. The closing of the offering is expected to occur on or about July 20, 2020, subject to the satisfaction of customary closing conditions.

Genetic Technologies Announces $5.1 Million Registered Direct Offering

Genetic Technologies Provides Update on COVID-19 Disease Severity Test

MELBOURNE, Australia, June  23, 2020  (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its interim-CEO Dr. George Muchnicki will share insight into the Company’s recent developments during an investor webinar, hosted by RedChip Companies, on Wednesday, June 24, 2020 at 4:00 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation.

Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020

MELBOURNE, Australia, May  28, 2020  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced public offering of 3,500,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS, and 500,000 pre-funded warrants, at an effective purchase price of $1.9999 per pre-funded warrant, for aggregate gross proceeds of approximately $8.0 million. Each pre-funded warrant sold in this offering is exercisable into one ADS at an exercise price of $0.0001 per ADS.

Genetic Technologies Announces Closing of $8.0 Million Public Offering

MELBOURNE, Australia, May  26, 2020  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000   American Depositary Shares (“ADSs”) (or ADS equivalents), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00   per ADS (or ADS equivalent). The closing of the offering is expected to occur on or about May 28, 2020, subject to the satisfaction of customary closing conditions.

Genetic Technologies Announces Pricing of $8.0 Million Public Offering

MELBOURNE, Australia, May  22, 2020  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) provides the following operational updates:

Genetic Technologies Provides Operational Update - Successful Prototype Polygenic Risk Score for COVID-19 Created

MELBOURNE, Australia, May  20, 2020  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to predict an individual’s risk of developing life-threatening complications should they become infected with COVID-19.

Genetic Technologies - Accelerated development of new COVID-19 Polygenic Risk Test for Risk of Developing Life-Threatening Complications

Temporary transition to high throughput COVID-19 testing Temporary transition to high throughput COVID-19 testing

COVID-19 Testing Capacity at Genetic Technologies Accredited Laboratory

MELBOURNE, Australia, April  06, 2020  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of the previously announced registered direct offering of 1,028,574 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $1.75 per ADS.

Genetic Technologies Announces Closing of $1.8 Million Registered Direct Offering

Genetic Tech (GENE) news for Wednesday includes GENE stock falling after the release of consumer tests for breast and colorectal cancer.

Genetic Tech News: GENE Stock Drops 13% Despite Consumer Cancer Tests

MELBOURNE, Australia, April  01, 2020  (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,028,574 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $1.75 per ADS. The closing of the offering is expected to occur on or about April 3, 2020, subject to the satisfaction of customary closing conditions.

News for Genetic Technologies Stock (GENE)